• Explore /
  • Poster
  • / Comparative efficacy of teclistamab (tec) versus current treatments (tx) in real-world clinical practice in the prospective LocoMMotion study in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).

Comparative efficacy of teclistamab (tec) versus current treatments (tx) in real-world clinical practice in the prospective LocoMMotion study in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM).

Abstract Video & Slides Poster

Authors

null

Niels W.C.J. van de Donk

Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

Niels W.C.J. van de Donk , Philippe Moreau , Michel Delforge , Hermann Einsele , Francesca Ghilotti , Joris Diels , Ahmed Elsada , Vadim Strulev , Lixia Pei , Rachel Kobos , Jennifer Smit , Mary Slavcev , Katja Weisel , Maria-Victoria Mateos

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8016)

DOI

10.1200/JCO.2022.40.16_suppl.8016

Abstract #

8016

Poster Bd #

440

Abstract Disclosures

Similar Posters

First Author: Philippe Moreau

First Author: Saad Zafar Usmani

First Author: Maria-Victoria Mateos

First Author: Robert M. Rifkin